Biogen (BIIB) said research and development, upfront payments and milestone charges are expected to reduce earnings by about $0.95 a share in Q2 and by $1.75 to $1.95 in Q3, reflecting potential milestones and transactions that haven't yet closed.
Results for the quarter ended June 30 have not been finalized, the company said Wednesday in a regulatory filing.